By Monalisa Breazu, Learning & Development Administrator
Back by popular demand after a superb GTR 2024.
What's this all about?
Cycle from Cambridge (with the ex-pro cyclist Yanto Critchlow-Barker 🚴♀️), Oxford or London meeting up at a pub in The Chilterns for a special biotech networking event in support of the children's medical research charity Action Medical Research.
KSBB-AFOB 2025 Conference marks the combined celebration of the 40th Anniversary Meeting and International Symposium of the Korean Society for Biotechnology and Bioengineering (KSBB) and the 17th Asian Congress on Biotechnology (ACB 2025). The conference will take place from September 23rd to 27th, 2025, in Incheon, Korea. Through the collaboration of KSBB and the Asian Federation of Biotechnology (AFOB), KSBB-AFOB Conference 2025 will serve as a premier venue for showcasing and exchanging the latest advancements in the rapidly growing field of biotechnology.
Building on the success of the 2024 summit, the 7th Exosome Based Therapeutic Development Summit returns with a refreshed program, with data-driven insights from those pioneering the field who are dedicated to the clinical translation and commercialization of exosome-based therapeutics across a broad range of disease indications.
Recent scientific developments, particularly in antibody engineering, have led to numerous innovations in cancer immunotherapy and one of the most promising innovations has been the development of bispecific antibodies, as bispecific drugs make huge waves in multiple myeloma and lymphoma, so much so that they threaten cell therapy in multiple myeloma.
Creative Biolabs has recently made upgrades to its CAR-T preclinical research, further enhancing the safety and functional evaluation of these therapies.
By Philippa Clark, Director of Business Development, One Nucleus
Cambridge Tech Week is a global tech gathering designed to unite the brightest minds - visionaries, world-leading experts, and strategic investors - to drive growth, collaboration, and transformative innovation across the tech ecosystem.
Devens, MA, USA — Veranova, a global leader in the development and manufacture of specialty and complex active pharmaceutical ingredients (API) for the pharmaceutical and biotech sectors, announced today that a routine current Good Manufacturing Practice (cGMP) surveillance inspection of Veranova’s Devens, Massachusetts site, completed by the Food and Drug Administration (FDA) New England District on July 31, 2025, concluded without any Form 483s and with a “No Action Indicated” (NAI) classification. This result demonstrates Veranova’s commitment to driving the highest standards of qu
Need to move faster from preclinical to first-in-human? CMC timelines for IND/CTA submissions can make or break a development plan. In this webinar, our CMC and regulatory experts will share how to avoid common bottlenecks and build submission strategies aligned with both FDA and EMA expectations.
o What typically causes delays when filing in both the US and EU?
o How can early CMC planning shorten your submission timeline?
o What support can you tap into from regulators today?